Disease · MONDO_0007027
metabolic dysfunction-associated steatohepatitis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. metabolic dysfunction-associated steatohepatitis. Diseases, record MONDO_0007027. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007027
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- MASH, NASH, NASH - nonalcoholic steatohepatitis, non alcoholic steatohepatitis, nonalcoholic steatohepatitis
- Open Targets
- Highest stage of its drugs
- Phase 3, for 31 of its 138 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs138
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VITAMIN E | CHEMBL3989727 | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets | |
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| SEMAGLUTIDE | CHEMBL2108724 | Protein | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| EFRUXIFERMIN | CHEMBL4594389 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PENTOXIFYLLINE | CHEMBL628 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| SAROGLITAZAR | CHEMBL4297530 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 3 | Drugs and targets |
| SELONSERTIB | CHEMBL3916717 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| SURVODUTIDE | CHEMBL5314776 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CENICRIVIROC | CHEMBL2110727 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 138
See all 138 drugsTargets181
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | 7 | Glucagon-like peptide 1 receptor agonist | Phase 3 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor | 7 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| NR1H4 | Bile acid receptor | 6 | Bile acid receptor FXR agonist | Phase 3 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 5 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| SLC5A2 | Sodium/glucose cotransporter 2 | 5 | Sodium/glucose cotransporter 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/6524 | Drugs and targets |
| GCGR | Glucagon receptor | 4 | Glucagon receptor agonist | Phase 3 | https://conductscience.org/library/genes/2642 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 4 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor delta agonist | Phase 3 | https://conductscience.org/library/genes/5467 | Drugs and targets |
| THRB | Thyroid hormone receptor | 3 | Thyroid hormone receptor agonist; Thyroid hormone receptor beta-1 agonist | Phase 3 | https://conductscience.org/library/genes/7068 | Drugs and targets |
| ACACA | Acetyl-CoA carboxylase | 2 | Acetyl-CoA carboxylase inhibitor; Acetyl-CoA carboxylase negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/31 | Drugs and targets |
| ACACB | Acetyl-CoA carboxylase | 2 | Acetyl-CoA carboxylase inhibitor; Acetyl-CoA carboxylase negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/32 | Drugs and targets |
1 to 10 of 181
See all 181 targetsTrials233
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02548351 | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment | Phase 3 | 2,477 | 2024-09-05 | Non Alcoholic Steatohepatitis (NASH) | OBETICHOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02704403 | Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) | Phase 3 | 2,157 | 2022-03-23 | Nonalcoholic Steatohepatitis (NASH) With Fibrosis | ELAFIBRANOR | Its record names the disease | ClinicalTrials.gov |
| NCT03028740 | AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) | Phase 3 | 1,778 | 2022-03-10 | Nonalcoholic Steatohepatitis | CENICRIVIROC | Its record names the disease | ClinicalTrials.gov |
| NCT03053063 | Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Phase 3 | 883 | 2020-05-07 | Nonalcoholic Steatohepatitis | SELONSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT03053050 | Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Phase 3 | 808 | 2020-06-29 | Nonalcoholic Steatohepatitis | SELONSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT04971785 | Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 457 | 2025-11-26 | Nonalcoholic Steatohepatitis | CILOFEXOR, FIRSOCOSTAT, SEMAGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03449446 | Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 395 | 2020-12-03 | Nonalcoholic Steatohepatitis | CILOFEXOR, FIRSOCOSTAT, SELONSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT02855164 | Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) | Phase 2 | 350 | 2021-07-29 | Non-alcoholic Steatohepatitis (NASH) | TROPIFEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT04771273 | A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | Phase 2 | 295 | 2024-12-03 | Non-alcoholic Steatohepatitis (NASH) | SURVODUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02217475 | Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis | Phase 2 | 289 | 2019-05-10 | Nonalcoholic Steatohepatitis | CENICRIVIROC | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 233
See all 233 trialsComparisons in its trials61
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 120 mg Elafibranor vs Placebo: deaths from any cause | 6 of 1,437 | 3 of 720 | 2,157 | NCT02704403 | Trial comparisons |
| 120 mg Elafibranor vs Placebo: serious adverse events | 190 of 1,433 | 95 of 717 | 2,150 | NCT02704403 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: deaths from any cause | 6 of 1,185 | 2 of 593 | 1,778 | NCT03028740 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: serious adverse events | 159 of 1,180 | 70 of 589 | 1,769 | NCT03028740 | Trial comparisons |
| 120 mg Elafibranor vs Placebo: Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage | 176 of 717 | 79 of 353 | 1,070 | NCT02704403 | Trial comparisons |
| 120 mg Elafibranor vs Placebo: Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis | 138 of 717 | 52 of 353 | 1,070 | NCT02704403 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 1 | 11 of 145 | 8 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and no Concurrent Worsening of Fibrosis at Year 1 | 23 of 145 | 27 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 7 of 145 | 4 of 144 | 289 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 29 of 145 | 15 of 144 | 289 | NCT02217475 | Trial comparisons |
1 to 10 of 61
See all 61 comparisons in its trialsPapers from its trials198
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007027
GET https://conductscience.org/api/diseases/v1/MONDO_0007027/drugs?page=2